Mark Booth (Probiodrug AG (Euronext Amsterdam: PBD))

Booth, Mark (Probiodrug 201603–201608 CBO LEFT 8/16 before Orexigen + Takeda + Immunex + Abbott)

	Organisation	Probiodrug AG (Euronext Amsterdam: PBD)
	Today	Vivoryon Therapeutics AG (Euronext Amsterdam: VVY)
	Group	Vivoryon (Group)
	Product	QC inhibitor (glutam(in)yl cyclase inhibitor)
	Product 2	public relations / investor relations / marcom (services)

Record changed: 2017-04-09

Picture EBD Group World of Partnering Opportunities 650x200px

More documents for Mark Booth

[1] Probiodrug AG. (3/30/17). "Press Release: Probiodrug Reports Full Year 2016 Financial Results". Halle (Saale)....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)